

ASX Announcement

Medibio Limited – 19 March 2021



Medibio Begins Implementation of ilumen In the United Kingdom

Melbourne, Australia and Minneapolis, United States – 19 March 2021: Medibio Limited (MEB or the Company)(ASX: MEB)(OTCPINK: MDBIF), is pleased to announce that it has signed the first Statement of Works agreement with Compass Group Plc to begin the implementation of ilumen in the UK.

Ilumen is a corporate mental health software product that provides an employer rich, de-identified, aggregated data to measure and manage the mental wellbeing of its workforce, whilst providing the employee a mental wellbeing “snapshot” so they may make improvements over time. Employees identified as high risk receive a confidential, personalized notification.

Medibio and Compass Group PLC entered into a Global Master Service Agreement (“Master Agreement”) in November 2020 to establish an agreed-upon framework for the efficient implementation of ilumen by Compass subsidiaries. Subsidiaries can implement ilumen simply by agreeing to a Statement of Works (**SOW**), which details the number of employees eligible to participate. All other materials terms and conditions of implementation are set forth in the Master Agreement and incorporated by reference.

The SOW marks the first stage of the ilumen roll out to the Compass UK workforce and provides for the participation of 1,000 employees for a minimum period of 12 months. Medibio will make further announcements regarding other Compass subsidiaries in due course.

SVP of Corporate Health at Medibio, Jennifer Solitario said:

“We are delighted to begin the implementation of ilumen with Compass UK. Compass is a priority, and our discussions with subsidiaries have been progressing nicely, so it is especially rewarding to solidify this arrangement with Compass UK. These companies will act as an excellent reference point as we expand our global outlook for ilumen.”

– ENDS –

This announcement is authorized for release to the market by the Board of Directors of Medibio Limited

About Medibio Limited

Medibio (ASX: MEB) (OTCPINK: MDBIF) is a health technology company pioneering the use of objective measures to aid in the early detection and screening of mental health conditions. Through their Corporate Health product, the Company offers mental well-being solutions for businesses and are also developing products to serve the healthcare provider market. The company was founded in Australia, with offices located in Melbourne (Vic) and U.S. offices in Minneapolis, MN. Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTC Pink Open Market. Investors can find additional information on www.otcm Markets.com and www.asx.com.au.

Medibio Investor and Media Enquiries:

WE Communications

WE-AUMedibio@we-worldwide.com

T: +61 (0) 404 369 388

Level 4, 100 Albert Road, South Melbourne, Vic 3205
Email: info@medibio.com.au | www.medibio.com.au